Marginal Zone Lymphoma

Showing 1 - 25 of 68

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (AS-1763)

Not yet recruiting
  • B-cell Malignancy
  • +7 more
  • (no location specified)
Oct 26, 2022

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Aug 19, 2022

B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor

Recruiting
  • B-Cell Lymphoma
  • +8 more
  • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
  • Pittsburgh, Pennsylvania
    AHN Cancer Institute - West Penn Hospital
Aug 10, 2022

Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,

Withdrawn
  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • +8 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 2, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Concord, California
  • +210 more
Jul 28, 2022

Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib, Rituximab, Bendamustine)

Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +134 more
Jul 27, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • EO2463
  • +2 more
  • Boston, Massachusetts
  • +9 more
Jul 26, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma Trial in Japan (epcoritamab

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • epcoritamab (monotherapy)
  • +5 more
  • Chuo Ku, Japan
  • +19 more
Jul 19, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 20, 2022

Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

Recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • Miami, Florida
    University of Miami
Jul 12, 2022

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Allogeneic Gamma Delta (?d) CAR T Cells

Enrolling by invitation
  • Lymphoma, Follicular
  • +5 more
  • ADI-001
  • Stanford, California
  • +4 more
Jun 7, 2022

Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma Trial in United States (ADI-001, Fludarabine,

Recruiting
  • Lymphoma, Follicular
  • +5 more
  • ADI-001
  • +2 more
  • Stanford, California
  • +4 more
Jun 7, 2022

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Apr 11, 2022

Marginal Zone Lymphoma Trial in Austria, Germany (Copanlisib, Rituximab)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +19 more
Mar 14, 2022

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
Mar 24, 2022

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Collecting and Storing Tissue Samples From Rare or Cutaneous

Active, not recruiting
  • Adult Immunoblastic Lymphoma
  • +12 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +129 more
Mar 23, 2022